Report Highlights

Pharmaceutical Coating Equipment in the U.S.: Market Overview

The U.S. pharmaceutical coating equipment market was valued at USD 0.62 billion in 2024 and is forecast to reach USD 0.91 billion by 2032. Demand is concentrated in oral solid dosage manufacturing, where film-coated and enteric-coated tablets dominate output at generic and branded sites. Government has shaped this form chiefly through regulation, as FDA's current Good Manufacturing Practice rules in 21 CFR Parts 210 and 211 set the performance standards that determine which coating technologies manufacturers adopt.

Private manufacturers have led equipment innovation, with Glatt, Freund Corporation and Syntegon supplying most high-throughput pan and fluid bed systems. Government has acted as a demand catalyst mainly through procurement and reshoring, notably the Defense Production Act Title III programme and the Industrial Base Management and Supply Chain office within the Administration for Strategic Preparedness and Response (ASPR). Private capital still funds most purchases, so policy shapes the timing of investment more than total volume.

Policy-Driven Growth in U.S. Coating Equipment

FDA's Process Analytical Technology framework, introduced in its 2004 guidance and extended by ICH Q13 on continuous manufacturing, allows manufacturers to monitor coating thickness and weight gain in real time. Executive Order 14017, America's Supply Chains, issued on 24 February 2021, directed agencies to strengthen domestic pharmaceutical capacity, which ASPR and Defense Production Act Title III awards translate into capital support for U.S. generic plants.

The growth mechanism runs through qualification. Each continuous or PAT-instrumented coater requires validation, which creates replacement demand as sites retire batch pan coaters. Section 168(k) of the Internal Revenue Code, restored to 100% bonus depreciation by the One Big Beautiful Bill Act in July 2025, lets plants expense these purchases in the first year, shortening payback and accelerating orders.

Regulatory Barriers and Compliance Costs

FDA administers the approval pathway, and any coating equipment change that alters an approved process requires a supplement under 21 CFR 314.70. A prior approval supplement carries a four-month FDA review goal, so a change to coating parameters can delay product launch by a full quarter. Equipment qualification through IQ/OQ/PQ validation commonly costs USD 150,000 to 400,000 per coating line.

EPA regulates solvent emissions under the National Emission Standards for Hazardous Air Pollutants for Pharmaceuticals Production, 40 CFR Part 63 Subpart GGG, which requires control of volatile organic compounds from solvent-based coating operations. OSHA's Combustible Dust National Emphasis Program, CPL 03-00-008, and NFPA 652 require dust hazard analysis and explosion protection for powder coating systems. Federal purchases of coating equipment must also comply with the Buy American Act under FAR Part 25.

Policy-Created Opportunities in the U.S.

ASPR's Industrial Base Management and Supply Chain office and Defense Production Act Title III awards create procurement demand for domestic generic oral solid dosage capacity, favouring pan and fluid bed coaters installed in U.S. plants. Vendors that offer U.S.-based service and spare-parts depots, such as Glatt's American operations, are positioned to win these awards.

Containment of highly potent active pharmaceutical ingredients is a second opportunity. OSHA and NIOSH occupational exposure banding guidance pushes OEB 4 and OEB 5 products toward closed, isolated coating systems, creating demand for contained coaters with integrated cleaning-in-place. Section 168(k) lowers the cost of this capital for contract development and manufacturing organisations.

Market at a Glance

Leading Market Participants

• Syntegon Technology
• Glatt
• Freund Corporation
• ACG Worldwide
• IMA Group
• GEA Group
• Hüttlin
• Vector Corporation
• Romaco
• Bosch Packaging Technology

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act, administered by the Food and Drug Administration through its Office of Pharmaceutical Quality. Its current Good Manufacturing Practice requirements in 21 CFR Parts 210 and 211, together with annual establishment registration under 21 CFR Part 207, govern coating equipment specification, validation and change control. EPA's 40 CFR Part 63 Subpart GGG and OSHA's combustible dust rules apply in parallel.

PDUFA VIII negotiations are underway ahead of the 30 September 2027 expiry of PDUFA VII, and FDA is expected to expand advanced manufacturing commitments in that cycle. Compared with regional peers, the U.S. framework is performance-based, while EU GMP Annex 1, revised with effect from 25 August 2023, prescribes contamination control more explicitly. China's NMPA GMP sits between these models, drawing on EU-style prescriptive requirements for sterile products.

Long-Term Policy Outlook for U.S. Coating Equipment

By 2032, FDA's continuous manufacturing expectations under ICH Q13 will become the default for new oral solid dosage approvals, shifting the installed base from batch pan coaters toward inline PAT-equipped systems. Advanced Manufacturing Technologies designation under the Food and Drug Omnibus Reform Act (FDORA) gives sponsors regulatory credit for such lines, reinforcing that shift.

Trade and onshoring policy will raise domestic equipment demand relative to imports from Germany and Italy, where most high-throughput coaters originate. The Section 232 investigation into pharmaceutical imports, initiated by the Department of Commerce in April 2025, will shape the cost of imported coating systems and favour U.S. installation and service capacity.